Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01783821 · ClinicalTrials.gov registry record · Phase 2
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT01783821: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01783821 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01783821, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
This study tested whether inhaled budesonide and formoterol were able to alleviate or prevent pulmonary injury when administered early in hospital course to the patients at risk for developing acute respiratory distress syndrome (ARDS). The FDA has approved many uses for budesonide and formoterol, including asthma and chronic obstructive pulmonary disease (COPD), but the use of these two drugs is experimental for ARDS.
Interventions
- DRUG Placebo
- DRUG Budesonide
- DRUG Formoterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01783821
The ClinicalTrials.gov registry entry for NCT01783821 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01783821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01783821 about?
NCT01783821 is a clinical study titled "LIPS-B: Lung Injury Prevention Study With Budesonide and Beta". This study tested whether inhaled budesonide and formoterol were able to alleviate or prevent pulmonary injury when administered early in hospital course to the patients at risk for developing acute respiratory distress syndrome (ARDS). The FDA has approved many uses for budesonide and formoterol, i...
What is the current status of trial NCT01783821?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2013-07. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01783821?
The interventions under investigation include: Placebo (DRUG), Budesonide (DRUG), Formoterol (DRUG).
Who is sponsoring clinical trial NCT01783821?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.